Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.
Ringshausen, F.C., Shapiro, A.J., Nielsen, K.G., Mazurek, H., Pifferi, M., Donn, K.H. et al. (2023).
The Lancet Respiratory Medicine, Volume 12, Issue 1, P21-33, JANUARY 2024